News | April 28, 2026
AstraZeneca wins US nod for at-home lupus treatment in major shift for SLE care
The approval was driven by data from the Phase III TULIP-SC trial
The approval was driven by data from the Phase III TULIP-SC trial
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
Originally established in Punjab, the Vasculitis Society of India is now expanding its footprint nationwide
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
The trial also demonstrated significant improvements across multiple secondary endpoints
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Subscribe To Our Newsletter & Stay Updated
